Atossa Genetics (ATOS)
(Delayed Data from NSDQ)
$1.46 USD
0.00 (0.00%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.46 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth B Momentum C VGM
Price, Consensus and EPS Surprise
ATOS 1.46 0.00(0.00%)
Will ATOS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ATOS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ATOS
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?
ATOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You Looking for a Top Momentum Pick? Why Atossa Genetics Inc. (ATOS) is a Great Choice
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?
Are Medical Stocks Lagging Alvotech (ALVO) This Year?
Other News for ATOS
Atossa Therapeutics announces support of final rule from FDA
Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer
Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
Atossa Therapeutics granted U.S. patent for endoxifen